Diaphragm Hibernation and Its Driving Factors in Mechanically Ventilated ICU Patients

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: Diaphragm Dysfunction; Weaning Invasive Mechanical Ventilation; Respiratory Failure, ICU Sponsors: Radboud University Medical Center Not yet recruiting Conditions: Diaphragm Dysfunction; Weaning Invasive Mechanical Ventilation; Respiratory Failure, ICU...

Compassion-Based Rehabilitation Needs Assessment Following Colorectal Cancer Surgery

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: Colonrectal Cancer; Colonrectal Cancer (CRC) Interventions: Behavioral: Compassionate Access Targeted Therapy Sponsors: Esbjerg Hospital – University Hospital of Southern Denmark Completed Conditions: Colonrectal Cancer; Colonrectal Cancer (CRC)...

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: Idiopathic Pulmonary Fibrosis Interventions: Drug: CHF10073 low dose; Drug: CHF10073 high dose; Drug: Placebo Sponsors: Chiesi Farmaceutici S.p.A. Not yet recruiting Conditions: Idiopathic Pulmonary Fibrosis Interventions: Drug: CHF10073 low dose; Drug:...

AI-Assisted Discharge Documents for Children and Families in a Pediatric Emergency Department

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: Health Communication; Patient Discharge Interventions: Other: Conventional Discharge Documentation Workflow; Other: LLM-Assisted Discharge Documentation Workflow Sponsors: University Hospital, Montpellier Completed Conditions: Health Communication;...

A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: High Risk Biochemical Recurrence (BCR); Deutenzalutamide Soft Capsules Interventions: Drug: Deutenzalutamide Soft Capsules + ADT; Drug: Placebo + ADT Sponsors: Hinova Pharmaceuticals Inc. Not yet recruiting Conditions: High Risk Biochemical Recurrence...

A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive

by palligoelme@gmail.com | Oct 15, 2026 | Clinical Trials

​ Conditions: Muscle-Invasive Bladder Cancer (MIBC) Interventions: Drug: Durvalumab; Drug: Gemcitabine; Drug: Cisplatin Sponsors: AstraZeneca Not yet recruiting Conditions: Muscle-Invasive Bladder Cancer (MIBC) Interventions: Drug: Durvalumab; Drug: Gemcitabine; Drug:...